| David Kendall Goebel, MD | |
|
617 23rd St, Suite 19, Ashland, KY 41101-2845 | |
| (606) 325-2221 | |
| (606) 324-1326 |
| Full Name | David Kendall Goebel |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 31 Years |
| Location | 617 23rd St, Ashland, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306845474 | NPI | - | NPPES |
| 64266216 | Medicaid | KY | |
| 0941431 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 35.067749 (Ohio) | Secondary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | 26621 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| King's Daughters' Medical Center | Ashland, KY | Hospital |
| Kings Daughters Medical Center Ohio | Portsmouth, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kings Daughters Medical Specialties Inc | 6103968029 | 328 |
| Kings Daughters Medical Specialties Inc | 6103968029 | 328 |
News Archive
Savient Pharmaceuticals, Inc. provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2015 Annual General Meeting of Shareholders held on Tuesday, August 11, 2015 in Beijing, PRC.
Finding a drug that targets only the diseased cells in our body and is otherwise harmless to healthy tissue is a goal for cancer researchers. It's driven the work of Professor Laurence Patterson, Director of the Institute of Cancer Therapeutics at the University of Bradford, and his team of researchers.
A gene linked to mental disorders helps lays the foundation for a crucial brain structure during prenatal development, according to Salk Institute research published January 14, 2016 in Cell Reports.
LDR, a privately held medical device company offering innovative spinal implants for both non-fusion and fusion applications, announced that it has received an Approvable Letter from the U.S. Food and Drug Administration (FDA) for its Mobi-C® Cervical Disc (Mobi-C). Mobi-C is a metal and polyethylene mobile bearing prosthesis specifically designed as a low-profile cervical intervertebral disc replacement for both one and two level applications.
› Verified 5 days ago
| Entity Name | Kings Daughters Medical Specialties Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710215736 PECOS PAC ID: 6103968029 Enrollment ID: O20100217000538 |
News Archive
Savient Pharmaceuticals, Inc. provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2015 Annual General Meeting of Shareholders held on Tuesday, August 11, 2015 in Beijing, PRC.
Finding a drug that targets only the diseased cells in our body and is otherwise harmless to healthy tissue is a goal for cancer researchers. It's driven the work of Professor Laurence Patterson, Director of the Institute of Cancer Therapeutics at the University of Bradford, and his team of researchers.
A gene linked to mental disorders helps lays the foundation for a crucial brain structure during prenatal development, according to Salk Institute research published January 14, 2016 in Cell Reports.
LDR, a privately held medical device company offering innovative spinal implants for both non-fusion and fusion applications, announced that it has received an Approvable Letter from the U.S. Food and Drug Administration (FDA) for its Mobi-C® Cervical Disc (Mobi-C). Mobi-C is a metal and polyethylene mobile bearing prosthesis specifically designed as a low-profile cervical intervertebral disc replacement for both one and two level applications.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Kendall Goebel, MD Po Box 2379, Ashland, KY 41105-2379 Ph: (606) 408-6200 | David Kendall Goebel, MD 617 23rd St, Suite 19, Ashland, KY 41101-2845 Ph: (606) 325-2221 |
News Archive
Savient Pharmaceuticals, Inc. provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2015 Annual General Meeting of Shareholders held on Tuesday, August 11, 2015 in Beijing, PRC.
Finding a drug that targets only the diseased cells in our body and is otherwise harmless to healthy tissue is a goal for cancer researchers. It's driven the work of Professor Laurence Patterson, Director of the Institute of Cancer Therapeutics at the University of Bradford, and his team of researchers.
A gene linked to mental disorders helps lays the foundation for a crucial brain structure during prenatal development, according to Salk Institute research published January 14, 2016 in Cell Reports.
LDR, a privately held medical device company offering innovative spinal implants for both non-fusion and fusion applications, announced that it has received an Approvable Letter from the U.S. Food and Drug Administration (FDA) for its Mobi-C® Cervical Disc (Mobi-C). Mobi-C is a metal and polyethylene mobile bearing prosthesis specifically designed as a low-profile cervical intervertebral disc replacement for both one and two level applications.
› Verified 5 days ago
Padma Venkatraman, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 101 Ashland Dr, Ashland, KY 41101 Phone: 606-324-1996 Fax: 606-833-2430 | |
Amr Idris, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 613 23rd St Ste 230, Ashland, KY 41101 Phone: 606-324-4745 Fax: 606-324-4941 | |
Paula K Larsen, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1000 Ashland Dr Ste G1, Ashland, KY 41101 Phone: 606-408-4900 Fax: 606-408-6643 | |
Michael Don Canty, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 617 23rd St, Suite 11, Ashland, KY 41101 Phone: 606-324-3188 Fax: 606-329-2237 | |
Dr. Ryann Acquino Pangan, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 613 23rd St Ste 130, Ashland, KY 41101 Phone: 606-329-9335 Fax: 606-324-6383 | |
Dr. Francisco Fernandez-gonzalez, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 613 23rd St Ste 310, Ashland, KY 41101 Phone: 606-833-2161 | |
Dr. Chad Jacob Tarabolous, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 617 23rd St, Suite 19, Ashland, KY 41101 Phone: 606-325-2221 Fax: 606-324-1326 |